Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;28(3):e14713.
doi: 10.1111/petr.14713.

Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study

Luciana de Fatima Porini Custodio  1   2 , Suelen Bianca Stopa Martins  1 , Laila Almeida Viana  1 , Marina Pontello Cristelli  1 , Lucio Requião-Moura  1   2 , Charles Yea Zen Chow  1 , Suzana Friedlander Del Nero Camargo  1 , Monica Rika Nakamura  1 , Renato Demarchi Foresto  1 , Helio Tedesco-Silva  1   2 , Jose Medina-Pestana  1   2
Affiliations

Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study

Luciana de Fatima Porini Custodio et al. Pediatr Transplant. 2024 May.

Abstract

Background: This study aimed to compare the efficacy and safety of basiliximab (BAS) versus a single dose of anti-thymocyte globulin (r-ATG) induction therapy in pediatric kidney transplant recipients (KTRs).

Methods: This single-center retrospective comparative cohort study included all pediatric KTRs from May 2013 to April 2018 and followed up to 12 months. In the first period, all recipients received BAS, while from May 2016, a single 3 mg/kg dose of r-ATG was instituted. Maintenance therapy consisted of a calcineurin inhibitor plus prednisone plus azathioprine or mycophenolate.

Results: A total of 227 patients were included (BAS, n = 113; r-ATG, n = 114). The main combination of immunosuppressive drugs was tacrolimus, prednisone, and azathioprine in both groups (87% vs. 88%, p = .718). Patients receiving r-ATG showed superior survival-free of the composite endpoint (acute rejection, graft loss, or death; 76% vs. 61%, p = .003; HR 2.08, 1.29-3.34, p = .003) and lower incidence of biopsy-proven acute rejection (10% vs. 21%, p = .015). There was no difference in the overall incidence of CMV infection (33% vs. 37%, p = .457), PTLD (1% vs. 3%, p = .309), 30-day hospital readmissions (24% vs. 23%, p = .847), and kidney function at 12 months (86 ± 29 vs. 84 ± 30 mL/min/1.73m2, p = .614).

Conclusions: These data suggest that induction therapy with a single 3 mg/kg dose of r-ATG is associated with higher efficacy for preventing acute rejection and similar safety profile compared to BAS.

Keywords: basiliximab; induction therapy; pediatrics kidney transplant; thymoglobulin.

PubMed Disclaimer

References

REFERENCES

    1. Kidney Disease. Improving global outcomes (KDIGO) transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1‐S155.
    1. Cooperative European Pediatric Renal Transplant Initiative (CERTAIN) registry. Available from: www.certain‐registry.eu.
    1. Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR 2021 annual data report: kidney. Am J Transplant. 2023;23(2 Suppl 1):S21‐S120.
    1. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;2010:CD003897.
    1. Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus‐based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant. 2006;6:1666‐1672.

MeSH terms

LinkOut - more resources